New results from Phase III trials of LY 2605541 (basal insulin peglispro) for Type 1 Diabetes- Eli Lilly

In new IMAGINE-1 and IMAGINE-3 Phase III trial data, Eli Lilly and Company's LY 2605541 (basal insulin peglispro) demonstrated statistically significantly lower hemoglobin A1c (HbA1c) compared to insulin glargine at 26 and 52 weeks in people with type 1 diabetes. In IMAGINE-1 and IMAGINE-3, LY 2605541 demonstrated superiority in HbA1c compared to insulin glargine.

Significantly more patients taking LY 2605541 met the ADA's recommended HbA1c target of less than 7 percent and experienced lower rates of nocturnal hypoglycemia compared to those taking insulin glargine. In both trials � in which patients were taking both mealtime and basal insulin � there was a statistically significant increase in the rate of total hypoglycemia for patients taking LY 2605541 compared with those taking insulin glargine due to a higher rate of daytime hypoglycemic events. In both trials, patients treated with LY 2605541 experienced mean weight loss compared to weight gain in patients who took insulin glargine. In both trials, patients taking LY 2605541 had an increase in triglycerides compared to insulin glargine.

The rate of major adverse cardiac events MACE+ (cardiovascular death, non-fatal stroke, non-fatal MI and hospitalization due to unstable angina) was lower for patients taking LY 2605541 compared with those taking insulin glargine in IMAGINE-3. There were no MACE+ events in IMAGINE-1. Detailed results from the trials were presented at the American Diabetes Association's 75th Scientific Sessions.